宜明昂科-B(01541.HK) 公布,集团已获得中国国家药监局批准,IMM0306S(皮下制剂)治疗系统性红斑狼疮(SLE)的新药临床试验申请。目前,集团拥有IMM0306S的全球知识产权及商业化权利。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-06 16:25。)AASTOCKS新闻
Source Link宜明昂科-B(01541.HK) 公布,集团已获得中国国家药监局批准,IMM0306S(皮下制剂)治疗系统性红斑狼疮(SLE)的新药临床试验申请。目前,集团拥有IMM0306S的全球知识产权及商业化权利。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-06 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.